ELOS-B.ST
Elos Medtech AB (publ) [ELOS-B.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ELOS-B.ST Stock Summary
In the News
ELOS-B.ST Financial details
Company Rating
Buy
Market Cap
1.64B
Income
54.95M
Revenue
1.02B
Book val./share
97.8
Cash/share
14.55
Dividend
-
Dividend %
-
Employees
653
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
21.42
Forward P/E
-
PEG
-7.86
P/S
1.61
P/B
2.08
P/C
13.95
P/FCF
-103.66
Quick Ratio
0.4
Current Ratio
1.99
Debt / Equity
0.48
LT Debt / Equity
0.48
-
-
EPS (TTM)
6.82
EPS next Y
-
EPS next Q
-
EPS this Y
-0.75%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
27.5%
Revenue last 5Y
6.63%
Revenue Q/Q
-6.89%
EPS Q/Q
131.03%
-
-
-
-
SMA20
-4.71%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
5%
ROE
9%
ROC
0.11%
Gross Margin
35%
Oper. Margin
14%
Profit Margin
7%
Payout
11%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
185.0-295.0
52W High
-31.19%
52W Low
+9.73%
RSI
54.45
Rel Volume
1.71
Avg Volume
6.04K
Volume
10.32K
Perf Week
0.5%
Perf Month
-3.33%
Perf Quarter
-
Perf Half Y
-0.98%
-
-
-
-
Beta
1.21581
-
-
Volatility
1.54%, 8.46%
Prev Close
1.5%
Price
203
Change
0.5%
ELOS-B.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 84.85 | 85.45 | 71.89 | 89.69 | 110.13 | |
| Net income per share | 2.76 | 4.77 | 4.47 | 9.37 | 9.3 | |
| Operating cash flow per share | 8.69 | 12.7 | 15.56 | 13.01 | 13.42 | |
| Free cash flow per share | -1.82 | 0.48 | 8.56 | 2.41 | -1.11 | |
| Cash per share | 6.44 | 6.84 | 10.96 | 11.79 | 20.91 | |
| Book value per share | 66.92 | 66.92 | 66.97 | 78.64 | 98.97 | |
| Tangible book value per share | 30.28 | 31.79 | 35.52 | 44.88 | 62.2 | |
| Share holders equity per share | 66.92 | 66.92 | 66.97 | 78.64 | 98.97 | |
| Interest debt per share | 39.78 | 42.15 | 35.24 | 36.78 | 44.92 | |
| Market cap | 530.34M | 859.24M | 871.34M | 2.21B | 1.98B | |
| Enterprise value | 773.07M | 1.13B | 1.06B | 2.4B | 1.82B | |
| P/E ratio | 25.33 | 22.32 | 24.18 | 29.25 | 26.45 | |
| Price to sales ratio | 0.82 | 1.25 | 1.5 | 3.06 | 2.23 | |
| POCF ratio | 8.03 | 8.39 | 6.94 | 21.06 | 18.33 | |
| PFCF ratio | -38.27 | 222.72 | 12.62 | 113.86 | -221.68 | |
| P/B Ratio | 1.04 | 1.59 | 1.61 | 3.48 | 2.49 | |
| PTB ratio | 1.04 | 1.59 | 1.61 | 3.48 | 2.49 | |
| EV to sales | 1.2 | 1.64 | 1.82 | 3.32 | 2.04 | |
| Enterprise value over EBITDA | 8.07 | 9.02 | 8.96 | 15.14 | 10.2 | |
| EV to operating cash flow | 11.71 | 11.05 | 8.41 | 22.88 | 16.77 | |
| EV to free cash flow | -55.79 | 293.35 | 15.3 | 123.72 | -202.84 | |
| Earnings yield | 0.04 | 0.04 | 0.04 | 0.03 | 0.04 | |
| Free cash flow yield | -0.03 | 0 | 0.08 | 0.01 | 0 | |
| Debt to equity | 0.57 | 0.61 | 0.51 | 0.45 | 0.45 | |
| Debt to assets | 0.3 | 0.32 | 0.27 | 0.25 | 0.25 | |
| Net debt to EBITDA | 2.53 | 2.17 | 1.57 | 1.21 | -0.95 | |
| Current ratio | 1.95 | 2.21 | 2.14 | 2.18 | 3.54 | |
| Interest coverage | 3.7 | 5.25 | 5.82 | 9.88 | 0 | |
| Income quality | 2.32 | 2.02 | 2.9 | 1.07 | 1.44 | |
| Dividend Yield | 0 | 0.01 | 0 | 0.01 | 0 | |
| Payout ratio | 0 | 0.21 | 0 | 0.16 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.14 | 0.14 | 0.14 | 0.13 | |
| Research and developement to revenue | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 | |
| Intangibles to total assets | 0.29 | 0.27 | 0.25 | 0.24 | 0.21 | |
| Capex to operating cash flow | -1.21 | -0.96 | -0.45 | -0.82 | -1.08 | |
| Capex to revenue | -0.12 | -0.14 | -0.1 | -0.12 | -0.13 | |
| Capex to depreciation | -1.42 | -1.64 | -0.94 | -1.54 | -1.82 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 64.41 | 84.77 | 82.03 | 128.75 | 143.92 | |
| ROIC | 0.03 | 0.05 | 0.06 | 0.08 | 0.08 | |
| Return on tangible assets | 0.03 | 0.05 | 0.05 | 0.09 | 0.07 | |
| Graham Net | -41.73 | -37.55 | -29.78 | -29.52 | -30.84 | |
| Working capital | 147.68M | 167.21M | 178.29M | 207.73M | 395.38M | |
| Tangible asset value | 230.03M | 256.52M | 286.54M | 362.08M | 501.86M | |
| Net current asset value | -146.38M | -189.47M | -127.05M | -108.88M | -73.62M | |
| Invested capital | 0.57 | 0.61 | 0.51 | 0.45 | 0.45 | |
| Average receivables | 43.06M | 33.04M | 68.99M | 84.24M | 109.41M | |
| Average payables | 32.68M | 27.82M | 28.67M | 38.24M | 42.41M | |
| Average inventory | 153.99M | 170.02M | 166.34M | 165.31M | 201.44M | |
| Days sales outstanding | 0 | 34.98 | 45.25 | 48.72 | 50.21 | |
| Days payables outstanding | 26.46 | 16.75 | 33.04 | 31.95 | 27.68 | |
| Days of inventory on hand | 129.54 | 133.85 | 147.17 | 134.51 | 145.46 | |
| Receivables turnover | 0 | 10.43 | 8.07 | 7.49 | 7.27 | |
| Payables turnover | 13.8 | 21.8 | 11.05 | 11.42 | 13.18 | |
| Inventory turnover | 2.82 | 2.73 | 2.48 | 2.71 | 2.51 | |
| ROE | 0.04 | 0.07 | 0.07 | 0.12 | 0.09 | |
| Capex per share | -10.52 | -12.22 | -7.01 | -10.6 | -14.53 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 28.65 | 34.42 | 33.12 | 33.29 | 31.17 | |
| Net income per share | 2.71 | 0.07 | 2.91 | 1.16 | 2.68 | |
| Operating cash flow per share | 6.84 | 2.76 | 1.62 | 4.27 | 3.6 | |
| Free cash flow per share | 3.17 | -1.6 | -2.27 | 0.25 | -3.11 | |
| Cash per share | 23.26 | 25.31 | 18.39 | 17.46 | 14.55 | |
| Book value per share | 100.73 | 119.77 | 101.93 | 105.55 | 97.8 | |
| Tangible book value per share | 60.65 | 75.28 | 63.6 | 65.47 | 57.66 | |
| Share holders equity per share | 100.73 | 119.77 | 101.93 | 105.55 | 97.8 | |
| Interest debt per share | 47.73 | 54.36 | 51.54 | 50.19 | 48.56 | |
| Market cap | 1.92B | 1.64B | 1.77B | 1.8B | 1.72B | |
| Enterprise value | 1.74B | 1.47B | 2.03B | 1.66B | 1.6B | |
| P/E ratio | 21.96 | 911.11 | 18.88 | 47.84 | 19.87 | |
| Price to sales ratio | 8.31 | 7.15 | 6.64 | 6.67 | 6.83 | |
| POCF ratio | 34.78 | 89.24 | 135.49 | 51.99 | 59.2 | |
| PFCF ratio | 75.13 | -153.95 | -96.99 | 899.48 | -68.4 | |
| P/B Ratio | 2.36 | 2.05 | 2.16 | 2.1 | 2.18 | |
| PTB ratio | 2.36 | 2.05 | 2.16 | 2.1 | 2.18 | |
| EV to sales | 7.5 | 6.41 | 7.59 | 6.14 | 6.37 | |
| Enterprise value over EBITDA | 30.5 | 58.36 | 32.61 | 34.25 | 27.25 | |
| EV to operating cash flow | 31.38 | 80.06 | 154.81 | 47.9 | 55.15 | |
| EV to free cash flow | 67.79 | -138.11 | -110.82 | 828.73 | -63.72 | |
| Earnings yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | -0.01 | -0.01 | 0 | -0.01 | |
| Debt to equity | 0.46 | 0.45 | 0.49 | 0.45 | 0.48 | |
| Debt to assets | 0.25 | 0.25 | 0.28 | 0.26 | 0.24 | |
| Net debt to EBITDA | -3.3 | -6.69 | 4.07 | -2.92 | -2 | |
| Current ratio | 3.15 | 3.54 | 3.56 | 3.47 | 1.99 | |
| Interest coverage | 3.43 | 0 | 3.1 | 1.71 | 3.17 | |
| Income quality | 1.91 | 40.84 | 0.43 | 2.53 | 0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0.86 | 0 | |
| Sales general and administrative to revenue | 0.13 | 0.13 | 0.11 | 0.15 | 0.16 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Intangibles to total assets | 0.22 | 0.21 | 0.21 | 0.22 | 0.21 | |
| Capex to operating cash flow | -0.54 | -1.58 | -2.4 | -0.94 | -1.87 | |
| Capex to revenue | -0.13 | -0.13 | -0.12 | -0.12 | -0.22 | |
| Capex to depreciation | -1.76 | -1.78 | -1.84 | -1.91 | -3.04 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 78.37 | 13.49 | 81.73 | 52.49 | 76.79 | |
| ROIC | 0.02 | 0 | 0.03 | 0.02 | 0.02 | |
| Return on tangible assets | 0.02 | 0 | 0.02 | 0.01 | 0.02 | |
| Graham Net | -58.62 | -37.32 | -59.43 | -63.39 | -81.23 | |
| Working capital | 398.9M | 395.38M | 406.8M | 411.9M | 288.1M | |
| Tangible asset value | 490.1M | 501.86M | 513.1M | 530.5M | 464.7M | |
| Net current asset value | -77.6M | -73.62M | -62.2M | -76.4M | -194.1M | |
| Invested capital | 0.46 | 0.45 | 0.49 | 0.45 | 0.48 | |
| Average receivables | 0 | 61.12M | 61.12M | 0 | 0 | |
| Average payables | 0 | 21.93M | 21.93M | 0 | 0 | |
| Average inventory | 0 | 115.19M | 115.19M | 0 | 0 | |
| Days sales outstanding | 0 | 47.95 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 24.21 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 127.19 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 1.88 | 0 | 0 | 0 | |
| Payables turnover | 0 | 3.72 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0.71 | 0 | 0 | 0 | |
| ROE | 0.03 | 0 | 0.03 | 0.01 | 0.03 | |
| Capex per share | -3.68 | -4.35 | -3.89 | -4.02 | -6.71 |
ELOS-B.ST Frequently Asked Questions
What is Elos Medtech AB (publ) stock symbol ?
Elos Medtech AB (publ) is a SE stock and trading under the symbol ELOS-B.ST
What is Elos Medtech AB (publ) stock quote today ?
Elos Medtech AB (publ) stock price is $203 today.
Is Elos Medtech AB (publ) stock public?
Yes, Elos Medtech AB (publ) is a publicly traded company.
Company Profile
- Volume Average 6.04K
- Market Capitalization 1.64B
- Employee 653
- CEO Mr. Stefano Alfonsi
- Headquarters Gothenburg,SE
- IPO Date 2000-01-03
-
Website
https://elosmedtech.com 
Elos Medtech AB (publ) engages in the development and contract manufacturing of medical devices and components for dental, orthopedics, diagnostics, and hearing and other medical device markets. It offers implants, screws, plates, orthopedic and dental instruments, drills, pins and wires, dental prosthetics, disposable plastic products, and HPLC fittings, as well as other medical plastic parts. The company also provides design and development, regulatory, prototyping, testing, OEM, process validation, and supply and inventory management, as well as design for manufacturing and engineering services. It has operations in Sweden, Denmark, China, and the United States. The company was formerly known as Elos AB (publ) and changed its name to Elos Medtech AB (publ) in April 2015. Elos Medtech AB (publ) was incorporated in 1923 and is headquartered in Gothenburg, Sweden.
